[Overall survival prediction scale for patients with grade 4 brain astrocytoma].

[OBJECTIVE] To create a prognostic scale for overall survival in grade 4 astrocytomas based on molecular biological data.

[MATERIAL AND METHODS] After morphological confirmation of WHO grade 4 astrocytoma (2021 WHO classification criteria), 175 patients were classified as GBM (grade 4) without mutations; mutation was detected in 25 patients (12.5%; G4 astrocytoma). Molecular biological analysis of gene mutations and MGMT promoter methylation was performed in 194 (97%) patients.

[RESULTS] To study concomitant significance of mutation and MGMT promoter methylation in grade 4 gliomas, we created the /MGMT index(0 - +/MGMT+; 1 - /MGMT (+/-); 2 - -/MGMT-). This predictor was digitized in 194 patients who underwent molecular analysis. The most informative classification matrix according to overall survival was as follows: /MGMT index (OR=1.712; =0.0004), REP (OR=1.971; =0.0001), functional status before microsurgery at the lowest possible level (OR=1.797; =0.001). Simple summation of numerical indicators for factors 1-3 in each patient allowed us to identify 5 prognostic classes: class 1 (0-1 points), class 2 (2 points), class 3 (3 points), class 4 (4 points), class 5 (5 points). Log-rank criterion for Kaplan-Meier survival curves revealed significant differences between classes (=55.780; <0.001). The median survival rates were 71.5, 42.3, 23.6, 17.4 and 8.1 months, respectively. Significant differences in survival were noted between almost all neighboring classes: classes 1-2 (=3.21; =0.073), classes 2-3 (=5.77; =0.016), classes 3-4 (=6.03; =0.014), classes 4-5 (=11.97; =0.0005). In "classes 1-3" in prognostic scale, median overall survival was 44.98 months (=53; 95% CI: 20.5-69.4) for 3 Gy fractionation regimen and only 23.23 months (=78; 95% CI: 17.3-29.1; =9.28; =0.002) for 2 Gy regimen. There were other results for classes 4-5. Median overall survival for 3 and 2 Gy fractionation regimens was low: 17.41 (=28; 95% Cl: 13.8-21.0) and 15.83 months (=41; 95% Cl: 11.7-20.0; -2=0.59; =0.442), respectively.

[CONCLUSION] The new prognostic scale for overall survival, based on molecular data, allows not only to predict further course of disease, but also to recommend irradiation 3 Gy for patients in classes 1-3 as an alternative to radiotherapy.